Welcome to our dedicated page for Adc Therapeutics Sa news (Ticker: ADCT), a resource for investors and traders seeking the latest updates and insights on Adc Therapeutics Sa stock.
ADC Therapeutics SA reports news on its commercial-stage oncology business focused on antibody-drug conjugates. The company markets ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC with FDA accelerated approval and European Commission conditional approval for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.
Recurring updates cover ZYNLONTA product revenue, manufacturing and commercialization activity, clinical development in combination regimens and earlier lines of therapy, including LOTIS program studies, and corporate financing matters. Company news also includes quarterly financial results, investor presentations, conference participation and equity inducement grants under its compensation plans.
ADC Therapeutics (NYSE: ADCT), a commercial-stage leader in antibody drug conjugates (ADCs), has scheduled its fourth quarter and year-end 2024 financial results conference call for March 27, 2025, at 8:30 a.m. EDT. The company will present financial performance and provide operational updates during the call.
Participants can join through a toll-free dial-in number (1-800-836-8184 for North America and Canada) and are advised to connect 10 minutes before the event. A live webcast will be accessible through the Investors section of ADC Therapeutics' website, with a 30-day replay available afterward.
ADC Therapeutics (NYSE: ADCT) has granted stock options to three new employees to purchase a total of 26,800 common shares on February 3, 2025. The grants were approved by the Compensation Committee as material inducement to employment under the Company's Inducement Plan, aiming to motivate high performance and significant contributions to company success.
The stock options will vest over four years, with 25% vesting on the first anniversary and the remaining vesting monthly at 1/48th of the total shares, contingent on continued employment. The grants were made under NYSE's Listed Company Manual Rule 303A.08 employment inducement exemption.
ADC Therapeutics (NYSE: ADCT), a commercial-stage leader in antibody drug conjugates (ADCs), has announced its participation in the upcoming Guggenheim SMID Cap Biotech Conference. CEO Ameet Mallik will engage in a fireside chat scheduled for Thursday, February 6, 2025, at 2:00 p.m. ET.
The presentation will be accessible through a live webcast on the Events & Presentations page of ADC Therapeutics' investor relations website section. Interested parties who cannot attend the live session can access a replay of the webcast, which will remain available for approximately 30 days following the event.
ADC Therapeutics SA (NYSE: ADCT) has announced the granting of stock options to two new employees on January 2, 2025. The grants total 20,000 common shares and were approved by the Company's Compensation Committee as material inducement to employment under the Company's Inducement Plan.
The options will vest over four years, with 25% vesting on the first anniversary and 1/48th vesting monthly thereafter, contingent on continued employment. The grants were made under NYSE's Listed Company Manual Rule 303A.08 employment inducement exemption.
ADC Therapeutics (NYSE: ADCT) announced completion of enrollment in LOTIS-5, a Phase 3 confirmatory trial evaluating ZYNLONTA combined with rituximab for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). The study aims to confirm ZYNLONTA's 2021 accelerated FDA approval and potentially expand its label for 2L+ treatment with rituximab.
Part 1 of the trial showed promising results with an 80% overall response rate and 50% complete response rate. Part 2 randomizes patients 1:1 to receive ZYNLONTA with rituximab versus rituximab-gemcitabine-oxaliplatin. Topline results are expected by end of 2025, with potential FDA submission in Q1 2026 and approval targeted for late 2026.
ADC Therapeutics (NYSE: ADCT) announced positive initial data from the LOTIS-7 Phase 1b trial evaluating ZYNLONTA® in combination with glofitamab for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The combination demonstrated a 94% best overall response rate and 72% complete response rate in evaluable patients.
The study included 29 B-NHL patients, with 18 evaluable 2L+ DLBCL patients receiving doses of 120 µg/kg or 150 µg/kg. At the 150µg/kg dose level, the combination achieved a 100% overall response rate and 78% complete response rate. Safety data showed no dose-limiting toxicities, with manageable Grade 3+ adverse events including neutropenia (24%), lymphopenia (7%), and hypokalemia (7%).
ADC Therapeutics announced updated data from two clinical trials evaluating ZYNLONTA®. In the first trial, ZYNLONTA combined with rituximab for relapsed/refractory follicular lymphoma showed a 97.4% overall response rate and 76.9% complete response rate, with 12-month progression-free survival of 94.6%. The study enrolled 39 patients with a median age of 68 years.
In the second trial, ZYNLONTA as monotherapy for relapsed/refractory marginal zone lymphoma demonstrated a 91% overall response rate and 70% complete response rate in 23 patients. The median duration of complete response was 11.5 months, with the longest follow-up at 27 months.
ADC Therapeutics (NYSE: ADCT) has announced a conference call and webcast scheduled for December 11, 2024, at 8:30 a.m. EST. The company will present preliminary data from the LOTIS-7 Phase 1b clinical trial, which evaluates ZYNLONTA® in combination with bispecific antibody glofitamab (COLUMVI™) for treating relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).
The conference call will be accessible via toll-free dial-in for North America and Canada participants, and a webcast will be available on the company's investor relations website for 30 days following the presentation.
ADC Therapeutics announced the granting of options to purchase 34,900 common shares to three new employees as employment inducement. The grants, approved by the Compensation Committee under the Company's Inducement Plan, will vest over four years, with 25% vesting on the first anniversary and 1/48th monthly thereafter until full vesting on the fourth anniversary, contingent on continued employment. The grants were made under NYSE's Listed Company Manual Rule 303A.08 employment inducement exemption.
ADC Therapeutics reported Q3 2024 financial results with ZYNLONTA® net product revenues of $18.0 million, up from $14.3 million in Q3 2023. The company reported a net loss of $44.0 million ($0.42 per share) compared to $46.7 million in Q3 2023. Key operational updates include expected full enrollment in LOTIS-5 trial by year-end 2024, continued LOTIS-7 enrollment with interim data expected in December, and discontinuation of the ADCT-601 program. Cash position stands at $274.3 million, with runway extended into mid-2026 following a $97.4 million offering in May 2024.